C5 and paroxysmal nocturnal hemoglobinuria: Pegcetacoplan is approved for the treatment of adult PNH patients in the United States (EMPAVELITM) [1], for adult PNH patients who are anemic after treatment with a complement factor C5 inhibitor for at least 3 months in Europe (ASPAVELI©) [4] and for adult PNH patients who are anemic after treatment with a C5 inhibitor for at least 3 months or intolerant to C5 inhibitors in Australia (EMPAVELI) [5].